Skip to content
2000
image of Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective
file format pdf download PDF

Abstract

Controversy exists around the relative merits of Fc functions in controlling or preventing HIV-1 infection. Proponents point to general correlations of Fc functions with control of HIV, indicating that non-neutralizing antibodies could force immune escape, as observed in the early experiments with Fc mutants of the b12-neutralizing monoclonal antibody. Nay-sayers point to the primary role of neutralization in the control of HIV, the general failure of vaccine trials including antibodies with Fc functions, and the lack of additional benefit with newer broadly neutralizing Ab, such as PGT121. The truth may lie somewhere in between and there are lessons to be learned from the utility of Fc functions in other viral infections. In general, however, the additional benefit of Fc function over and above robust anti-HIV neutralizing antibodies may be modest. The intense primary research focus on delivering and inducing potent and broadly neutralizing antibodies, regardless of their Fc function potential, is justified.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X353682250314070148
2025-03-25
2025-10-18

  • From This Site

    /content/journals/chr/10.2174/011570162X353682250314070148
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/chr/10.2174/011570162X353682250314070148/BMS-CHIVR-2024-HT10-6091-1.html?itemId=/content/journals/chr/10.2174/011570162X353682250314070148&mimeType=html&fmt=ahah

References

  1. Hessell A.J. Jaworski J.P. Epson E. Matsuda K. Pandey S. Kahl C. Reed J. Sutton W.F. Hammond K.B. Cheever T.A. Barnette P.T. Legasse A.W. Planer S. Stanton J.J. Pegu A. Chen X. Wang K. Siess D. Burke D. Park B.S. Axthelm M.K. Lewis A. Hirsch V.M. Graham B.S. Mascola J.R. Sacha J.B. Haigwood N.L. Early short-term treatment with neutralizing human Ab halts SHIV infection in infant macaques. Nat. Med. 2016 22 4 362 368 10.1038/nm.4063 26998834
    [Google Scholar]
  2. Liu J. Ghneim K. Sok D. Bosche W.J. Li Y. Chipriano E. Berkemeier B. Oswald K. Borducchi E. Cabral C. Peter L. Brinkman A. Shetty M. Jimenez J. Mondesir J. Lee B. Giglio P. Chandrashekar A. Abbink P. Colantonio A. Gittens C. Baker C. Wagner W. Lewis M.G. Li W. Sekaly R.P. Lifson J.D. Burton D.R. Barouch D.H. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 2016 353 6303 1045 1049 10.1126/science.aag0491 27540005
    [Google Scholar]
  3. Shapiro M.B. Cheever T. Malherbe D.C. Pandey S. Reed J. Yang E.S. Wang K. Pegu A. Chen X. Siess D. Burke D. Henderson H. Lewinsohn R. Fischer M. Stanton J.J. Axthelm M.K. Kahl C. Park B. Lewis A.D. Sacha J.B. Mascola J.R. Hessell A.J. Haigwood N.L. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nat. Commun. 2020 11 1 70 10.1038/s41467‑019‑13972‑y 31911610
    [Google Scholar]
  4. Nishimura Y. Gautam R. Chun T.W. Sadjadpour R. Foulds K.E. Shingai M. Klein F. Gazumyan A. Golijanin J. Donaldson M. Donau O.K. Plishka R.J. Buckler-White A. Seaman M.S. Lifson J.D. Koup R.A. Fauci A.S. Nussenzweig M.C. Martin M.A. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 2017 543 7646 559 563 10.1038/nature21435 28289286
    [Google Scholar]
  5. Bolton D.L. Pegu A. Wang K. McGinnis K. Nason M. Foulds K. Letukas V. Schmidt S.D. Chen X. Todd J.P. Lifson J.D. Rao S. Michael N.L. Robb M.L. Mascola J.R. Koup R.A. Human immunodeficiency virus type 1 Ab suppress acute simian-human immunodeficiency virus viremia and limit seeding of cell-associated viral reservoirs. J. Virol. 2016 90 3 1321 1332 10.1128/JVI.02454‑15 26581981
    [Google Scholar]
  6. Corey L. Gilbert P.B. Juraska M. Montefiori D.C. Morris L. Karuna S.T. Edupuganti S. Mgodi N.M. deCamp A.C. Rudnicki E. Huang Y. Gonzales P. Cabello R. Orrell C. Lama J.R. Laher F. Lazarus E.M. Sanchez J. Frank I. Hinojosa J. Sobieszczyk M.E. Marshall K.E. Mukwekwerere P.G. Makhema J. Baden L.R. Mullins J.I. Williamson C. Hural J. McElrath M.J. Bentley C. Takuva S. Gomez Lorenzo M.M. Burns D.N. Espy N. Randhawa A.K. Kochar N. Piwowar-Manning E. Donnell D.J. Sista N. Andrew P. Kublin J.G. Gray G. Ledgerwood J.E. Mascola J.R. Cohen M.S. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 2021 384 11 1003 1014 10.1056/NEJMoa2031738 33730454
    [Google Scholar]
  7. Ahmad R. Sindhu S.T.A.K. Toma E. Morisset R. Vincelette J. Menezes J. Ahmad A. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 2001 21 3 227 233 10.1023/A:1011087132180 11403230
    [Google Scholar]
  8. Forthal D.N. Landucci G. Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res. Hum. Retrovir. 2001 17 6 553 561 10.1089/08892220151126661 11350669
    [Google Scholar]
  9. Forthal D.N. Landucci G. Daar E.S. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J. Virol. 2001 75 15 6953 6961 10.1128/JVI.75.15.6953‑6961.2001 11435575
    [Google Scholar]
  10. Nag P. Kim J. Sapiega V. Landay A.L. Bremer J.W. Mestecky J. Reichelderfer P. Kovacs A. Cohn J. Weiser B. Baum L.L. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J. Infect. Dis. 2004 190 11 1970 1978 10.1086/425582 15529262
    [Google Scholar]
  11. Chung A.W. Isitman G. Navis M. Kramski M. Center R.J. Kent S.J. Stratov I. Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc. Natl. Acad. Sci. USA 2011 108 18 7505 7510 10.1073/pnas.1016048108 21502492
    [Google Scholar]
  12. Chung A.W. Navis M. Isitman G. Wren L. Silvers J. Amin J. Kent S.J. Stratov I. Activation of NK cells by ADCC antibodies and HIV disease progression. J. Acquir. Immune Defic. Syndr. 2011 58 2 127 131 10.1097/QAI.0b013e31822c62b9 21792067
    [Google Scholar]
  13. Wren L.H. Chung A.W. Isitman G. Kelleher A.D. Parsons M.S. Amin J. Cooper D.A. Stratov I. Navis M. Kent S.J. Specific antibody‐dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013 138 2 116 123 10.1111/imm.12016 23173935
    [Google Scholar]
  14. Forthal D.N. Finzi A. Antibody-dependent cellular cytotoxicity in HIV infection. AIDS 2018 32 17 2439 2451 10.1097/QAD.0000000000002011 30234611
    [Google Scholar]
  15. Richard J. Prévost J. Alsahafi N. Ding S. Finzi A. Impact of HIV-1 envelope conformation on ADCC responses. Trends Microbiol. 2018 26 4 253 265 10.1016/j.tim.2017.10.007 29162391
    [Google Scholar]
  16. Lee W.S. Prévost J. Richard J. van der Sluis R.M. Lewin S.R. Pazgier M. Finzi A. Parsons M.S. Kent S.J. CD4- and time-dependent susceptibility of HIV-1-infected cells to antibody-dependent cellular cytotoxicity. J. Virol. 2019 93 10 e01901-18 10.1128/JVI.01901‑18 30842324
    [Google Scholar]
  17. Hessell A.J. Hangartner L. Hunter M. Havenith C.E.G. Beurskens F.J. Bakker J.M. Lanigan C.M.S. Landucci G. Forthal D.N. Parren P.W.H.I. Marx P.A. Burton D.R. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007 449 7158 101 104 10.1038/nature06106 17805298
    [Google Scholar]
  18. Rerks-Ngarm S. Pitisuttithum P. Nitayaphan S. Kaewkungwal J. Chiu J. Paris R. Premsri N. Namwat C. de Souza M. Adams E. Benenson M. Gurunathan S. Tartaglia J. McNeil J.G. Francis D.P. Stablein D. Birx D.L. Chunsuttiwat S. Khamboonruang C. Thongcharoen P. Robb M.L. Michael N.L. Kunasol P. Kim J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009 361 23 2209 2220 10.1056/NEJMoa0908492 19843557
    [Google Scholar]
  19. Haynes B.F. Gilbert P.B. McElrath M.J. Zolla-Pazner S. Tomaras G.D. Alam S.M. Evans D.T. Montefiori D.C. Karnasuta C. Sutthent R. Liao H.X. DeVico A.L. Lewis G.K. Williams C. Pinter A. Fong Y. Janes H. DeCamp A. Huang Y. Rao M. Billings E. Karasavvas N. Robb M.L. Ngauy V. de Souza M.S. Paris R. Ferrari G. Bailer R.T. Soderberg K.A. Andrews C. Berman P.W. Frahm N. De Rosa S.C. Alpert M.D. Yates N.L. Shen X. Koup R.A. Pitisuttithum P. Kaewkungwal J. Nitayaphan S. Rerks-Ngarm S. Michael N.L. Kim J.H. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 2012 366 14 1275 1286 10.1056/NEJMoa1113425 22475592
    [Google Scholar]
  20. Rerks-Ngarm S. Pitisuttithum P. Excler J.L. Nitayaphan S. Kaewkungwal J. Premsri N. Kunasol P. Karasavvas N. Schuetz A. Ngauy V. Sinangil F. Dawson P. deCamp A.C. Phogat S. Garunathan S. Tartaglia J. DiazGranados C. Ratto-Kim S. Pegu P. Eller M. Karnasuta C. Montefiori D.C. Sawant S. Vandergrift N. Wills S. Tomaras G.D. Robb M.L. Michael N.L. Kim J.H. Vasan S. O’Connell R.J. Randomized, double-blind evaluation of late boost strategies for HIV-uninfected vaccine recipients in the RV144 HIV vaccine efficacy trial. J. Infect. Dis. 2017 215 8 1255 1263 10.1093/infdis/jix099 28329190
    [Google Scholar]
  21. Easterhoff D. Moody M.A. Fera D. Cheng H. Ackerman M. Wiehe K. Saunders K.O. Pollara J. Vandergrift N. Parks R. Kim J. Michael N.L. O’Connell R.J. Excler J.L. Robb M.L. Vasan S. Rerks-Ngarm S. Kaewkungwal J. Pitisuttithum P. Nitayaphan S. Sinangil F. Tartaglia J. Phogat S. Kepler T.B. Alam S.M. Liao H.X. Ferrari G. Seaman M.S. Montefiori D.C. Tomaras G.D. Harrison S.C. Haynes B.F. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. PLoS Pathog. 2017 13 2 e1006182 10.1371/journal.ppat.1006182 28235027
    [Google Scholar]
  22. Akapirat S. Karnasuta C. Vasan S. Rerks-Ngarm S. Pitisuttithum P. Madnote S. Savadsuk H. Rittiroongrad S. Puangkaew J. Phogat S. Tartaglia J. Sinangil F. de Souza M.S. Excler J.L. Kim J.H. Robb M.L. Michael N.L. Ngauy V. O’Connell R.J. Karasavvas N. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One 2018 13 4 e0196397 10.1371/journal.pone.0196397 29702672
    [Google Scholar]
  23. Pitisuttithum P. Nitayaphan S. Chariyalertsak S. Kaewkungwal J. Dawson P. Dhitavat J. Phonrat B. Akapirat S. Karasavvas N. Wieczorek L. Polonis V. Eller M.A. Pegu P. Kim D. Schuetz A. Jongrakthaitae S. Zhou Y. Sinangil F. Phogat S. Diazgranados C.A. Tartaglia J. Heger E. Smith K. Michael N.L. Excler J.L. Robb M.L. Kim J.H. O’Connell R.J. Vasan S. Pitisuthitham A. Sabmee Y. Sirisopana N. Eamsila C. Savaraj P. Labwech W. Teerachia S. Chotirosniramit N. Supindham T. Pruenglampoo B. Sugandhavesa P. Kosashunhanan N. Kaewthip O. Sroysuwan P. Jarujareet P. Ratto-Kim S. Molnar S. Schoen J. Churikanont N. Getchalarat S. Sangnoi N. Nuntapinit B. Phramtong A. Grandin P.V. Madnote S. Rittiroongrad S. Kaewboon B. Trichavaroj R. Puangkaew J. Chantakulkij S. Rakyat P. Panjapornsuk P. Tragonlugsana N. Chuenarom W. de Souza M. Ngauy V. Phanuphak N. Chomchey N. Saengtawan P. Teeratakulpisarn N. Rerknimitr R. Kroon E. Lee C.A. Chinaworapong S. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: A double-blind, randomised controlled trial. Lancet HIV 2020 7 4 e238 e248 10.1016/S2352‑3018(19)30406‑0 32035516
    [Google Scholar]
  24. Lazarus E.M. Otwombe K. Adonis T. Sebastian E. Gray G. Grunenberg N. Roux S. Churchyard G. Innes C. Laher F. Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa. PLoS One 2014 9 11 e112303 10.1371/journal.pone.0112303 25401780
    [Google Scholar]
  25. Gray G.E. Andersen-Nissen E. Grunenberg N. Huang Y. Roux S. Laher F. Innes C. Gu N. DiazGranados C. Phogat S. Lee C. Swann E. Kim J. O’Connell R. Michael N. Flach B. DeRosa S. Frahm N. Morris L. Montefiori D. Gilbert P. Tomaras G. McElrath J. Corey L. HVTN 097: Evaluation of the RV144 vaccine regimen in HIV uninfected South African adults. AIDS Res. Hum. Retrovir. 2014 30 S1 A33 A34 10.1089/aid.2014.5052a.abstract
    [Google Scholar]
  26. Bekker L.G. Moodie Z. Grunenberg N. Laher F. Tomaras G.D. Cohen K.W. Allen M. Malahleha M. Mngadi K. Daniels B. Innes C. Bentley C. Frahm N. Morris D.E. Morris L. Mkhize N.N. Montefiori D.C. Sarzotti-Kelsoe M. Grant S. Yu C. Mehra V.L. Pensiero M.N. Phogat S. DiazGranados C.A. Barnett S.W. Kanesa-thasan N. Koutsoukos M. Michael N.L. Robb M.L. Kublin J.G. Gilbert P.B. Corey L. Gray G.E. McElrath M.J. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: A phase 1/2 trial. Lancet HIV 2018 5 7 e366 e378 10.1016/S2352‑3018(18)30071‑7 29898870
    [Google Scholar]
  27. Burton D.R. Antiviral neutralizing antibodies: From in vitro to in vivo activity. Nat. Rev. Immunol. 2023 23 11 720 734 10.1038/s41577‑023‑00858‑w 37069260
    [Google Scholar]
  28. Asokan M. Dias J. Liu C. Maximova A. Ernste K. Pegu A. McKee K. Shi W. Chen X. Almasri C. Promsote W. Ambrozak D.R. Gama L. Hu J. Douek D.C. Todd J.P. Lifson J.D. Fourati S. Sekaly R.P. Crowley A.R. Ackerman M.E. Ko S.H. Kilam D. Boritz E.A. Liao L.E. Best K. Perelson A.S. Mascola J.R. Koup R.A. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl. Acad. Sci. USA 2020 117 31 18754 18763 10.1073/pnas.2008236117 32690707
    [Google Scholar]
  29. Wang P. Gajjar M.R. Yu J. Padte N.N. Gettie A. Blanchard J.L. Russell-Lodrigue K. Liao L.E. Perelson A.S. Huang Y. Ho D.D. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti–HIV-1 IgG1 antibodies in vivo. Proc. Natl. Acad. Sci. USA 2020 117 30 18002 18009 10.1073/pnas.2008190117 32665438
    [Google Scholar]
  30. Parsons M.S. Lee W.S. Kristensen A.B. Amarasena T. Khoury G. Wheatley A.K. Reynaldi A. Wines B.D. Hogarth P.M. Davenport M.P. Kent S.J. Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques. J. Clin. Invest. 2018 129 1 182 191 10.1172/JCI122466 30475230
    [Google Scholar]
  31. Blazkova J. Refsland E.W. Clarridge K.E. Shi V. Justement J.S. Huiting E.D. Gittens K.R. Chen X. Schmidt S.D. Liu C. Doria-Rose N. Mascola J.R. Heredia A. Moir S. Chun T.W. Glycan-dependent HIV-specific neutralizing antibodies bind to cells of uninfected individuals. J. Clin. Invest. 2019 129 11 4832 4837 10.1172/JCI125955 31589168
    [Google Scholar]
  32. Hangartner L. Beauparlant D. Rakasz E. Nedellec R. Hozé N. McKenney K. Martins M.A. Seabright G.E. Allen J.D. Weiler A.M. Friedrich T.C. Regoes R.R. Crispin M. Burton D.R. Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Sci. Transl. Med. 2021 13 585 eabe3349 10.1126/scitranslmed.abe3349 33731434
    [Google Scholar]
  33. Parsons M.S. Kristensen A.B. Selva K.J. Lee W.S. Amarasena T. Esterbauer R. Wheatley A.K. Bavinton B.R. Kelleher A.D. Grulich A.E. Khoury G. Juno J.A. Kent S.J. Protective efficacy of the anti-HIV broadly neutralizing antibody PGT121 in the context of semen exposure. EBioMedicine 2021 70 103518 10.1016/j.ebiom.2021.103518 34385004
    [Google Scholar]
  34. Moldt B. Shibata-Koyama M. Rakasz E.G. Schultz N. Kanda Y. Dunlop D.C. Finstad S.L. Jin C. Landucci G. Alpert M.D. Dugast A.S. Parren P.W.H.I. Nimmerjahn F. Evans D.T. Alter G. Forthal D.N. Schmitz J.E. Iida S. Poignard P. Watkins D.I. Hessell A.J. Burton D.R. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 2012 86 11 6189 6196 10.1128/JVI.00491‑12 22457527
    [Google Scholar]
  35. Stadler E. Chai K.L. Schlub T.E. Cromer D. Khan S.R. Polizzotto M.N. Kent S.J. Beecher C. White H. Turner T. Skoetz N. Estcourt L. McQuilten Z.K. Wood E.M. Khoury D.S. Davenport M.P. Determinants of passive antibody efficacy in SARS-CoV-2 infection: A systematic review and meta-analysis. Lancet Microbe 2023 4 11 e883 e892 10.1016/S2666‑5247(23)00194‑5 37924835
    [Google Scholar]
  36. Winkler E.S. Gilchuk P. Yu J. Bailey A.L. Chen R.E. Chong Z. Zost S.J. Jang H. Huang Y. Allen J.D. Case J.B. Sutton R.E. Carnahan R.H. Darling T.L. Boon A.C.M. Mack M. Head R.D. Ross T.M. Crowe J.E. Jr. Diamond M.S. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell 2021 184 7 1804 1820.e16 10.1016/j.cell.2021.02.026 33691139
    [Google Scholar]
  37. Suryadevara N. Shrihari S. Gilchuk P. VanBlargan L.A. Binshtein E. Zost S.J. Nargi R.S. Sutton R.E. Winkler E.S. Chen E.C. Fouch M.E. Davidson E. Doranz B.J. Chen R.E. Shi P.Y. Carnahan R.H. Thackray L.B. Diamond M.S. Crowe J.E. Jr. Neutralizing and protective human Ab recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021 184 9 2316 2331.e15 10.1016/j.cell.2021.03.029 33773105
    [Google Scholar]
  38. Ullah I. Beaudoin-Bussières G. Symmes K. Cloutier M. Ducas E. Tauzin A. Laumaea A. Grunst M.W. Dionne K. Richard J. Bégin P. Mothes W. Kumar P. Bazin R. Finzi A. Uchil P.D. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Rep. Med. 2023 4 1 100893 10.1016/j.xcrm.2022.100893 36584683
    [Google Scholar]
  39. Schäfer A. Muecksch F. Lorenzi J.C.C. Leist S.R. Cipolla M. Bournazos S. Schmidt F. Maison R.M. Gazumyan A. Martinez D.R. Baric R.S. Robbiani D.F. Hatziioannou T. Ravetch J.V. Bieniasz P.D. Bowen R.A. Nussenzweig M.C. Sheahan T.P. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. J. Exp. Med. 2021 218 3 e20201993 10.1084/jem.20201993 33211088
    [Google Scholar]
  40. Fielding C.A. Sabberwal P. Williamson J.C. Greenwood E.J.D. Crozier T.W.M. Zelek W. Seow J. Graham C. Huettner I. Edgeworth J.D. Price D.A. Morgan P.B. Ladell K. Eberl M. Humphreys I.R. Merrick B. Doores K. Wilson S.J. Lehner P.J. Wang E.C.Y. Stanton R.J. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 2022 11 e74489 10.7554/eLife.74489 35587364
    [Google Scholar]
  41. DiLillo D.J. Tan G.S. Palese P. Ravetch J.V. Broadly neutralizing hemagglutinin stalk–specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 2014 20 2 143 151 10.1038/nm.3443 24412922
    [Google Scholar]
  42. Ye Z.W. Yuan S. Poon K.M. Wen L. Yang D. Sun Z. Li C. Hu M. Shuai H. Zhou J. Zhang M.Y. Zheng B.J. Chu H. Yuen K.Y. Antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin head region of pandemic H1N1 influenza virus play detrimental roles in H1N1-infected mice. Front. Immunol. 2017 8 317 10.3389/fimmu.2017.00317 28377769
    [Google Scholar]
  43. Vanderven H.A. Wentworth D.N. Han W.M. Peck H. Barr I.G. Davey R.T. Jr. Beigel J.H. Dwyer D.E. Jain M.K. Angus B. Brandt C.T. Mykietiuk A. Law M.G. Neaton J.D. Kent S.J. Understanding the treatment benefit of hyperimmune anti-influenza intravenous immunoglobulin (Flu-IVIG) for severe human influenza. JCI Insight 2023 8 14 e167464 10.1172/jci.insight.167464 37289541
    [Google Scholar]
  44. Teo A. Tan H.D. Loy T. Chia P.Y. Chua C.L.L. Understanding antibody-dependent enhancement in dengue: Are afucosylated IgG1s a concern? PLoS Pathog. 2023 19 3 e1011223 10.1371/journal.ppat.1011223 36996026
    [Google Scholar]
  45. Kim H.W. Canchola J.G. Brandt C.D. Pyles G. Chanock R.M. Jensen K. Parrott R.H. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 1969 89 4 422 434 10.1093/oxfordjournals.aje.a120955 4305198
    [Google Scholar]
  46. van Erp E.A. Luytjes W. Ferwerda G. van Kasteren P.B. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Front. Immunol. 2019 10 548 10.3389/fimmu.2019.00548 30967872
    [Google Scholar]
  47. Gunn B.M. Yu W.H. Karim M.M. Brannan J.M. Herbert A.S. Wec A.Z. Halfmann P.J. Fusco M.L. Schendel S.L. Gangavarapu K. Krause T. Qiu X. He S. Das J. Suscovich T.J. Lai J. Chandran K. Zeitlin L. Crowe J.E. Jr. Lauffenburger D. Kawaoka Y. Kobinger G.P. Andersen K.G. Dye J.M. Saphire E.O. Alter G. A role for Fc function in therapeutic monoclonal antibody-mediated protection against ebola virus. Cell Host. Microbe. 2018 24 2 221 233.e5 10.1016/j.chom.2018.07.009 30092199
    [Google Scholar]
/content/journals/chr/10.2174/011570162X353682250314070148
Loading
Fc Functions and Anti-HIV Neutralizing Antibodies: A Perspective
Bentham Science Publishers ; https://doi.org/10.2174/011570162X353682250314070148
/content/journals/chr/10.2174/011570162X353682250314070148
/content/journals/chr/10.2174/011570162X353682250314070148
Loading

Data & Media loading...


  • Article Type:     Editorial
Keywords: Fc functions ; viral infections ; vaccine trials ; PGT121 ; HIV-1 infection ; Ab

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test